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Abstract
Background: It is currently impossible to predict the prognosis of patients with juvenile dermatomyositis (JDM).
The aim of this study was to find clinical features most strongly associated with outcome variables in JDM as a first
step towards tailor-made treatment.
Methods: In a large, prospectively followed, multicenter cohort study of 340 patients with JDM, each contributing
multiple visits, a Bayesian model of disease activity was developed, using the four continuous outcome variables
creatine kinase (CK), childhood myositis assessment score (CMAS), manual muscle testing of 8 muscle groups (MMT8)
and the physician’s global assessment of disease activity (PGA). Covariates were clinical signs and symptoms.
Correlations among visits of the same patient were resolved by introducing subject-specific random effects.
Results: Myalgia and dysphonia were associated with worse disease activity according to all outcome variables.
Periorbital rash, rash on the trunk, rash over large joints, nail fold changes and facial swelling were associated with
higher PGA. Notably, periorbital rash was also associated with higher CK and lower CMAS and nail fold changes with
lower CMAS. Contractures were associated with lower CMAS and MMT8 and higher PGA. Patients with higher CMAS
exhibited a higher MMT8 as well. PGA had the highest probability among the four outcome variables of being
abnormal even if the other three outcome variables were normal.
Conclusions: The signs and symptoms associated with disease activity could be used to stratify patients and adapt
treatment plans to disease activity. The correlation between CMAS and MMT8 and the unique information captured by
PGA implied that PGA should be maintained as an outcome variable, whereas CMAS and MMT8 might be simplified.
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Background
The childhood inflammatory idiopathic myopathies
(IIM) are a group of heterogeneous disorders, character-
ized by chronic skeletal muscle inflammation. Of these,
juvenile dermatomyositis (JDM) is the most common,
though still a rare disease with an incidence of about
1.9–4.1 per 1,000,000 children [1]. Its hallmark is muscle
inflammation characterized by proximal muscle weak-
ness, in concert with skin involvement presenting itself
typically as Gottron’s papules, heliotrope rash, malar
rash or erythema overlying the extensor surfaces of the
joints [2]. JDM potentially involves other internal organ
systems as well, most notably the gastrointestinal and
the respiratory tracts and patients with major organ in-
volvement have a poor prognosis [2]. JDM is heteroge-
neous in nature, in terms of disease severity and various
patterns of involvement of muscle, skin and internal
organ systems. About 24–40% of patients experience a
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monocyclic course, whereas 50–60% have chronic dis-
ease activity [2]. The mortality rate is around 2–3% [2].
Given the severity and burden of the disease and pos-
sible long-term complications, adequate treatment is of
utmost importance [2, 3]. A recent trial has shown that
the combination of prednisone and methotrexate has
the best potential to induce disease remission in
new-onset JDM [4]. Ideally, treatment is tailored to the
patient, in such a way that patients with high disease ac-
tivity, at risk of developing serious sequelae of the dis-
ease, receive early and aggressive treatment, whereas
those with less severe forms of the disease receive milder
therapy. Previous studies have revealed some clinical fac-
tors associated with a worse prognosis [1, 5, 6]. However,
in these reports disease activity was either taken dichot-
omously at a single point in time or was analyzed as
time to remission.
The aim of the current study was to find clinical signs
and symptoms associated with higher disease activity as
measured by four widely used continuous outcome vari-
ables, assessed longitudinally in a large, multicenter co-
hort of patients with JDM. Such associations with high
disease activity could be used in follow up studies to
predict disease outcome in patients with JDM as a first
step towards tailor-made treatment.
Methods
Patients were retrieved from the ongoing UK Juvenile
dermatomyositis cohort and biomarker study (JDCBS),
which started recruitment of patients with JDM across
the UK in 2000 [7]. Patients were enrolled at diagnosis
or shortly thereafter and followed up approximately
every 3 months for 2 years and subsequently at least an-
nually. At each visit, data were collected on signs and
symptoms of the disease, such as skin manifestations
(e.g., periorbital rash, periungual rash, Gottron’s papules,
nail fold changes, ulceration), muscular involvement
(e.g., muscle weakness, dyspnoea, dysphonia, dysphagia)
and symptoms of involvement of other organ systems
(e.g., arthritis, chest pain, abdominal pain, hematuria,
melena; see Additional file 1 for full list). Blood was
drawn for routine laboratory testing. Furthermore, data
were collected on treatment and disease activity accord-
ing to four widely used continuous outcome variables,
i.e., creatine kinase (CK), childhood myositis assessment
scale (CMAS) [8], manual muscle testing of 8 muscle
groups (MMT8) and the physician’s global assessment of
disease activity (PGA). These outcomes were selected
because they have been validated as a set of parameters
able to classify patients with JDM as active or inactive
[9]. Furthermore, they are widely used and readily avail-
able in routine daily care. However, rather than applying
previously published criteria for inactive disease and di-
chotomizing patients as active or inactive, we modeled
the four parameters in a continuous way, thus taking full
advantage of the information they contain.
Ethical approval was obtained by the multicenter eth-
ical review board covering all participating institutions.
All participants provided written informed consent, or
age-appropriate assent with parental consent. The study
was performed according to the declaration of Helsinki
and good clinical practice guidelines.
The UK JDM study enrolled patients with suspected
or definite myositis with symptoms starting before the
16th birthday. At the time of analysis, data on 469 pa-
tients from 4122 visits were available. Of these, 413 pa-
tients contributing 3881 visits met the inclusion criteria
of having probable or definite JDM according to the
Bohan and Peter criteria [10, 11].
Statistical analysis
The data were analyzed using a Bayesian approach. Details
of the analysis have been described elsewhere [12]. Briefly,
a mixed effect regression model was fitted, by specifying a
joint model for the four clinical outcome variables. These
outcome parameters were modeled as continuous vari-
ables. This approach allowed us to account for the correl-
ation among disease activity measures and, therefore,
better exploit the information contained in the variables,
compared to an analysis that considers the four outcomes
as independent and treats the responses as dichotomous.
In the analysis, CK values were log-transformed so that
the distribution of CK was closer to normal. On the other
hand, CMAS, MMT8 and PGA were square root trans-
formed, as they are non-negative variables potentially as-
suming value zero. More interestingly, these three
variables showed an excess of the best possible clinical
value for that parameter for visits of patients in disease re-
mission and a long tail towards the pathological end of
the scale. These distributional characteristics must be
accounted for in the analysis to avoid bias in the estimates.
As such we modeled CMAS, MMT8 and PGA using an
approach similar to hurdle models [13]. This approach
allowed the model to estimate many more visits of pa-
tients to be in disease remission than a standard linear re-
gression would do, thus mirroring the observed
distribution of the outcome parameters.
To make maximal use of the information contained in
the dataset, all visits of all patients were analyzed simul-
taneously. Temporal correlation between multiple visits
of the same patient was accounted for using a
subject-specific random intercept and, in the case of CK
level, a subject-specific random slope for the time since
diagnosis, in a way similar to a mixed model in a re-
peated measurements analysis [14]. Furthermore, due to
correlations between the four outcome parameters, the
four subject-specific random intercepts (one for each
outcome variable) were modeled by specifying a
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multivariate normal distribution as random effect distri-
bution. The covariance matrix of this distribution was
estimated from the data [15]. This allowed the assess-
ment of the correlation among the outcome parameters
(i.e., the correlation that measures whether one outcome
parameter tended to increase if another parameter in-
creased as well within the same individual over time).
Missing values in the covariates were imputed in the
Bayesian model, by specifying an appropriate model for
them. We did not impute missing values for the history
variables, since this would amount to imputing a partici-
pant’s recollection, the accuracy of which is doubtful.
Visits with any unobserved history variables were there-
fore excluded from the analysis.
The aim of the model was to find all clinical features
associated with disease activity. Therefore, all clinical
signs and symptoms and treatment variables, and the
time elapsed since diagnosis were eligible to be included
as independent variables in the model. Variable
pre-selection was performed by selecting 50% of the var-
iables using univariate linear mixed models. All treat-
ment covariates and the time elapsed since diagnosis
were included in the model, regardless of their perform-
ance in the univariate analysis. Bayesian variable selec-
tion on the pre-selected covariates was performed [16].
This approach yields the sparsest set of predictors that is
still able to estimate the outcome parameters accurately.
A predictor variable would either be included for all four
outcomes or excluded.
The goodness of fit of the model was assessed visually
by checking the fit of the model for patients with more
than 10 visits, by looking at 95% Bayesian credible inter-
vals (CI) for the disease trajectory over time. Further-
more, the ability of the model to predict values above or
below the validated cutoff points (CK ≤ 150, CMAS ≥
48, MMT8 ≥ 78 and PGA ≤ 0.2) [9], was assessed by cal-
culating the scaled Brier score. This score has a range
from 0 to 100% and has an interpretation similar to
Pearson’s R2 statistic [17]. The out-of-sample prediction
ability of the model was tested by randomly selecting
five fully observed patients and leaving them out while
fitting the model. The predicted values for the four out-
comes over time were then compared to the observed
values. Statistical analysis was performed in R 3.2.2 (R
foundation for statistical computing, Vienna, Austria)
and JAGS, using the package rjags [18].
Results
Due to exclusion of visits with missing data on history
variables, 340 of 413 patients were included in the ana-
lysis. Of these, the majority (69.4%) was female, the me-
dian age at diagnosis was 7.4 years (1st–3rd quartile
4.5–10.5) and disease duration since the onset of the
first symptoms was short (median 0.3 years, 1st–3rd
quartile 0.2–0.6). Patients contributing more visits to the
study were more likely to have at least one visit without
missing values in the history variables and were there-
fore more likely to be included. Excluded patients due to
missing data in the history variables appeared to have
shorter duration of follow up in the study, longer period
of time after diagnosis before enrollment and less active
disease (Table 1). The proportion of missing data in the
analyzed data set was 7.3%.
The goodness of fit of the model was good as evi-
denced by a plot of the observed values versus the pre-
dicted values and 95% Bayesian CI (Fig. 1). Over all
visits and outcome parameters, only 1.8% of observed
values were outside of the CIs. The scaled Brier score
was 49%, 42%, 63% and 80% of the maximally obtainable
Brier score for CK, CMAS, MMT8 and PGA, respect-
ively. The visual check of the out-of-sample predictions
showed accurate predictions of the four outcomes. Only
in two cases involving CMAS was the predicted value
above the cutoff point for inactive disease (48 points),
whereas the observed value was below, but in both these
cases the observed value was close to the cutoff point
(46 points and 47 points, respectively). The precision of
the predictions was modest as evidenced by wide predic-
tion CIs, owing to uncertainties in predictions, param-
eter estimation and missing value imputation.
Estimates of regression coefficients of the continuous
component of the model showed that CMAS, MMT8
and PGA tended to normalize over time, whereas hardly
any influence of time on CK was noted (Fig. 2). Many
muscular symptoms, such as myalgia and dysphonia
were associated with higher disease activity. Cutaneous
symptoms such as periorbital rash, rash on the trunk,
rash over large joints, nail fold changes and facial
Table 1 Baseline table
Parameter Included Excluded
N = 340 N = 73
Female, n (%) 236 (69.4) 54 (74.0)
Age at diagnosis, years 7.4 (4.5, 10.5) 7.3 (4.1, 11.1)
Disease duration at diagnosis, years 0.3 (0.2, 0.6) 0.3 (0.2, 1.0)
Time after diagnosis at enrollment, years 0.2 (0.1, 1.1) 2.3 (0.4, 5.4)
Duration of follow up, years 4.1 (1.6, 7.1) 1.2 (0.1, 2.6)
Disease activity at enrollment:
CK, U/L 103 (64, 440) 98 (45, 256)
CMAS, points 41 (21, 50) 46 (37, 52)
MMT8, points 65 (45, 80) 80 (64, 80)
PGA, cm 3 (1.3, 6.0) 2.3 (0.5, 4.0)
Values are the median (1st quartile, 3rd quartile), except where
indicated otherwise
Abbreviations: CK creatine kinase, cm centimeter, CMAS childhood myositis
assessment scale, MMT8 manual muscle testing of 8 muscle groups, PGA
physician’s global assessment of disease activity, U/L units per liter
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swelling were associated with higher disease activity and,
notably, were in some cases associated with more dis-
ease activity according to strictly muscular outcome pa-
rameters (e.g., periorbital rash was associated with
higher CK values and lower CMAS and nail fold changes
was associated with lower CMAS).
The presence of contractures was associated with
lower CMAS and MMT8 values and higher PGA,
whereas CK was not affected. An association was
found between calcinosis and higher CMAS and
PGA values. Joint swelling was associated with lower
CMAS, lower CK and higher PGA and the presence
of hematuria was accompanied by markedly elevated
CK levels. Of all signs and symptoms at baseline,
only arthritis was associated with increased CMAS
and MMT8.
The use of both cyclophosphamide and intravenous
(IV) steroids was associated with higher disease activity,
though cyclophosphamide was also associated with
lower CK levels. Conversely, oral steroids were associ-
ated with lower disease activity.
Correlations between the subject-specific random in-
tercepts showed that patients with a higher CMAS
tended to have a higher MMT8 as well (Table 2). Weak
correlation was found between MMT8 and PGA and
CMAS and PGA. All correlations between the
subject-specific random intercept for CK and the other
three parameters were low (Table 2).
Of visits during which three outcome variables had nor-
mal values, the median (1st, 3rd quartile) probability that
the predicted value for PGA remained abnormal (i.e. >
0.2) was estimated to be 52% (< 1, 78%). The median (1st,
3rd quartile) probability was 6% (2, 20%), 1% (< 1, 8%) and
1% (< 1, 17%), for CK, CMAS and MMT8 respectively.
Discussion
This study identified clinical signs and symptoms associ-
ated with four outcome parameters taken continuously
and longitudinally in a large, multicenter cohort of pa-
tients with JDM. This approach not only allowed to esti-
mate the associations between various signs and
symptoms and disease activity, but also enabled to assess
correlations among the outcome parameters, in order to
have a clearer understanding of disease activity by ac-
counting jointly for all the outcome values. The results
showed as expected that dysphonia, already known to be
a marker of severe disease activity [2], was associated
with higher disease activity. Hematuria was also associ-
ated with markedly elevated CK levels. Hematuria was
measured by urine dipstick, which gives a positive result
in the case of hematuria or myoglobinuria. In the
former, hematuria is an indication of severe systemic
(i.e., renal) disease. In the latter, myoglobinuria is due to
severe muscular involvement, leading to rhabdomyolysis.
Cutaneous symptoms were associated with PGA, the
only parameter taking account of cutaneous disease
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Fig. 1 Goodness of fit of the physician’s global assessment of disease activity. Observed values of the (square root transformed) parameter (dark
gray dots) for six randomly selected individuals were plotted against the predicted values by the model (dashed line) and the 95% CI (light gray
area), showing that the predicted values corresponded well to observed patterns over time. Goodness of fit of the other outcome parameters
was similar (not shown). Abbreviations: CI, credible interval; sqrt, square root; PGA, Physician’s global assessment of disease activity
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activity, but, interestingly, periorbital rash and nail fold
changes were also associated with lower CMAS values
and higher CK values, implying that cutaneous and
muscular disease were correlated. It could therefore be
hypothesized that the return of cutaneous symptoms in
a patient in disease remission signals an imminent
muscular relapse. This finding lends support to the
expert-based opinion that ongoing skin disease reflects
ongoing systemic disease activity [19]. Interestingly,
Gottron’s papules, pathognomonic of JDM, were not
associated with any outcome parameter.
The association between contractures and lower
CMAS and MMT8 values might be due to difficulty in
applying these instruments in the presence of contrac-
tures [20], especially given the absence of association
with CK. Likewise, the association between calcinosis
and higher CMAS levels might indicate that this
phenomenon occurred in a late stage of disease and
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Fig. 2 Regression coefficients and 95% credible intervals. Regression coefficients (dots) with 95% credible interval (horizontal lines) of the fixed
effects of time elapsed since diagnosis and all covariates in the model, for all outcomes. Regression coefficients to the left of the vertical dashed
line indicate the parameter is associated with lower values of the corresponding outcome measurement, and conversely for regression
coefficients to the right of the dashed line. Some credible intervals are collapsed to 0 (e.g., association between sex and log creatine kinase (CK)),
due to there not being any association at all. Abbreviations: sqrt, square root; CMAS, childhood myositis assessment scale; MMT8, manual muscle
testing of 8 muscle groups; PGA, physician’s global assessment of disease activity
Table 2 Estimated correlations with 95% credible intervals of
subject random intercepts for the four outcomes CK, CMAS,
MMT8 and PGA
Comparison ρ^ 95% CI
CK vs. CMAS 0.07 (−0.07, 0.23)
CK vs. MMT8 −0.001 (−0.16, 0.15)
CK vs. PGA 0.0007 (−0.15, 0.16)
CMAS vs. MMT8 0.54 (0.42, 0.65)
CMAS vs. PGA 0.17 (0.01, 0.32)
MMT8 vs. PGA 0.23 (0.08, 0.32)
Abbreviations: CI credible interval, CK creatine kinase, CMAS childhood myositis
assessment scale, MMT8 manual muscle testing of 8 muscle groups, PGA
physician’s global assessment
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persisted in disease remission. Yet, the results showed
that physicians gave higher PGA scores to patients with
calcinosis.
Arthritis at diagnosis was associated with increased
CMAS and MMT8, potentially due to a subset of pa-
tients with an overlap between JDM and juvenile idio-
pathic arthritis (JIA) with less severe muscular
inflammation [2]. Joint swelling at the visit was associ-
ated with a higher PGA and lower CMAS, possibly indi-
cating difficulty in executing the tasks of the CMAS in
the presence of arthritis.
The substantial correlation between the subject-specific
random intercepts for CMAS and MMT8 indicated that
patients with a higher CMAS tended to have a higher
MMT8, as reported previously [20]. This implied that in-
formation captured by CMAS was also partially captured
by MMT8 and vice versa. Conversely, in many visits
where CK, CMAS and MMT8 were normal, the model es-
timated PGA to be abnormal, implying that PGA captures
aspects of disease that are not measured by the other out-
come parameters. This was consistent with the observa-
tion that PGA was the only outcome parameter taking
account of cutaneous involvement and involvement of
other organs [21, 22]. Similar estimates for the other out-
come parameters in our model were much lower, indicat-
ing that these variables captured information already
conveyed by the other outcome measures. In conclusion,
our observations supported the previously made proposal
to increase the weight of PGA in the evaluation of JDM
disease activity, to account for cutaneous disease activity
[22]. Moreover, our results suggested that the three mus-
cular disease activity measures, mainly CMAS and
MMT8, could be shortened or even summarized into a
single instrument, thus saving precious time during busy
clinics, whilst retaining the same level of information.
The results of our study were in line with results ob-
tained previously [1, 5, 6]. In a large cohort of 490 pa-
tients with JDM, analyzing the dichotomized outcome
parameter at one time point, a mean of 7.7 years after
diagnosis, there was association between CMAS and
dysphagia and dysphonia [1]. This study also found an
increased probability of having a CMAS score of 52
points in patients with cutaneous symptoms at onset,
whereas in our study cutaneous manifestations (though
not at onset) were associated with a lower CMAS score
[1]. In a Canadian cohort of 84 patients, the persistence
of skin rash, especially Gottron’s papules, 3 months after
diagnosis was associated with a longer time to remission
[5]. However, given that disease remission was defined
in this study as absence of skin rash (including Gottron’s
papules), myositis and arthritis, this finding might be
tautological [5]. Gottron’s papules were not associated
with any of the four outcome parameters in our study.
In a retrospective study of 61 patients with JDM, a lower
skin disease activity score (DAS) at baseline was also as-
sociated with a monocyclic disease course [6].
A limitation to the current study is the lack of
auto-antibody and muscle biopsy data, and indeed any
other biomarkers in our data set. The antibody patterns
in the childhood IIM have been studied extensively and
were found to determine different subsets of the disease,
characterized among others by the distribution of skin
rash, contractures, dysphonia, dysphagia, and the out-
come of the disease [23, 24]. It would be interesting to
know if these different subsets entail varying prognoses.
Furthermore, prediction of outcome could be aided by
muscle biopsy findings [25, 26] and yet other biomarkers
may be found among blood plasma cytokines, chemo-
kines and other inflammation-related compounds.
The goal of our study was to find clinical signs and
symptoms associated with four frequently used disease
activity parameters [9, 22]. As a consequence, no other
outcome parameters, mainly cutaneous disease activity
measurements, were considered. Future work may ad-
dress this limitation; however, this would entail cutane-
ous symptoms that form part of the outcome
measurement no longer being available as predictors.
Likewise, our study did not contain patient-reported out-
comes, nor other important outcomes, such as physical
function, damage or health-related quality of life.
Hardly any features at baseline were associated with
disease activity at follow up. This was most probably be-
cause the model included also signs and symptoms dur-
ing follow up, the associations of which overwhelmed
associations with baseline variables. Future work may in-
vestigate the predictive ability of these signs and symp-
toms in the assessment of disease activity. Attention
should also be paid to the predictive ability of CK,
CMAS, MMT8 and PGA at baseline and efforts should
be undertaken to find out what variables are key to pre-
dicting disease outcome in JDM in order to identify a
parsimonious set of data that should be collected at all
clinical visits.
Finally, the exclusion of visits with missing history var-
iables, led to the exclusion of 73 patients who appeared
to have lower disease activity. This was probably due to
the fact they were enrolled in the study at a later time
point after diagnosis. Moreover, their follow up was
shorter than in patients who were included in the ana-
lysis (Table 1). Therefore, the exclusion of this biased
subset of patients was not considered problematic.
Conclusions
The associations between clinical signs and symptoms
and four continuous disease activity measurements in
this large, multicenter cohort of patients with JDM, who
were followed longitudinally, open up possibilities to
personalize treatment plans in JDM, by offering more
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aggressive treatment to patients with signs and symp-
toms associated with higher disease activity. Follow up
studies may attempt to predict future disease activity
using the clinical signs and symptoms that were associ-
ated with higher disease activity found in the current
study. Furthermore, the associations highlight interesting
patterns, such as the association between skin disease
and muscular outcome measures. Finally, the correla-
tions between the four outcome measurements provide
insight into unique information captured by each param-
eter and might be helpful in the determination of a par-
simonious set of outcome parameters in JDM, for
example by summarizing the CMAS and MMT8 in a
single instrument and increasing the importance of PGA
in the evaluation of disease remission.
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